Journal Press India^®

Author Details ( * ) denotes Corresponding author

Purpose: To study whether India is the right choice for pharmaceutical FDI in the near future. Design/Methodology/Approach: This study is based entirely on the secondary data. Data have been taken for study from various sources like Government of India, Annual Reports of the Controller General of Patents, Designs, Trademarks and Geographical Indications, Intellectual Property, various years, Chemical and Engineering News, Centre for Monitoring Indian Economy.s Prowess database, Government of India, Department of Industrial Policy and Promotion, Ministry of Commerce and Industry, Secretariat for Industrial Assistance, SIA Newsletter, United Nations, International Trade Statistics Yearbook Findings: There is a steep rise in both pharmaceutical as well as total patent applications after the setting up of the WTO in 1995. The Indian pharmaceutical industry as a whole is only 1.9 per cent of the industry’s turnover. The Government of India has not only abolished industrial licensing for bulk drugs, intermediates and formulations, but has allowed automatic FDI approvals up to 100 percent foreign ownership. Research Limitations: Point of view of pharmaceutical companies’ owners should have also been taken into the study to provide the real picture of government initiatives and its impact. Managerial Implications: The study may help the pharmaceutical companies to set up its goals in such a manner where they may take the leverage of the government’s initiatives. It may also work upon the available opportunities in the open market and may export the drugs and medicine to other countries. Originality/Value: This research paper is original in nature.

Keywords

Pharmaceutical Industry, TRIPs, Patent, Chemical and Engineering, Drugs, FDI.

1. Commercial Law Publishers (2003), The Patents Act, 1970, Commercial Law Publishers, Delhi.
2. Economic Survey (2004-05), Ministry of Finance, Government of India, New Delhi, India.
3. Kothari, A. (2003), ‘Facets of Indian Pharma R&D’, India Equity Research, Paper presented at Mumbai, April 2003.
4. Organization of Pharmaceutical Producers of India (OPPI) (2004), ‘Fact Sheet 2003’, Pharmaceutical Industry in India.
5. Panchal, S. (2005), ‘Patents Era: How will Pharma Firms Cope’? www.rediff.com, April 7, 2005.
6. Zimmerman, R. and J. Pesta (2001), ‘Drug Industry, AIDS Community is Jolted by Cipla AIDS-Drug Offer’, The Wall Street Journal, February 8, 2001.